Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 23; no. 16_suppl; p. 4726
Main Authors Dalgleish, A. G., Quatan, N., Michael, A., Wushishi, F., Pandha, H.
Format Journal Article
LanguageEnglish
Published 01.06.2005
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2005.23.16_suppl.4726